← brief for 2026-09-09 · Slowing decline

Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis

Paper A Peer reviewed Meta-analysis or large trial

Key takeaways

This review pooled many randomized trials in people who have both type 2 diabetes and chronic kidney disease. It compared three drug families against each other: GLP-1 drugs, SGLT2 inhibitors, and non-steroidal MRAs, which block a hormone that raises blood pressure and scars the kidney. It looked at heart and kidney outcomes and at side effects. Pooling randomized trials this way is the strongest kind of evidence for deciding which drug to reach for first.

Who did this work

Hongli Chen (China Academy of Chinese Medical Sciences) · Xuejie Wu (China Academy of Chinese Medical Sciences) · Mengyi Yuan (Beijing University of Chinese Medicine) · Feihong Ren (China Academy of Chinese Medical Sciences) · Tongtong Liu (China Academy of Chinese Medical Sciences) · Liping Yang (China Academy of Chinese Medical Sciences) · Xuedong An (China Academy of Chinese Medical Sciences) · Yongli Zhan (China Academy of Chinese Medical Sciences)

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-08
https://doi.org/10.3389/fendo.2026.1937754